Prospective comparative study of intraoperative balloon electronic brachytherapy versus resection with multidisciplinary adjuvant therapy for recurrent glioblastoma
Open Access
- 11 October 2021
- journal article
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 12, 517
- https://doi.org/10.25259/sni_494_2021
Abstract
Background: Intraoperative balloon electronic brachytherapy (IBEB) may provide potential benefit for local control of recurrent cerebral glioblastomas (GBMs). Methods: This is a preliminary report of an open-label, prospective, comparative cohort study conducted in two neurosurgical centers with ongoing follow-up. At recurrence, patients at one center (n = 15) underwent reresection with IBEB while, at the second center (n = 15), control subjects underwent re-resection with various accepted second-line adjuvant chemoradiotherapy options. A comparative analysis of overall survival (OS) and local progression-free survival (LPFS) following re-resection was performed. Exploratory subgroup analysis based on postoperative residual contrast-enhanced volume status was also done. Results: In the IBEB group, median LPFS after re-resection was significantly longer than in the control group (8.0 vs. 6.0 months; log rank χ2 = 4.93, P = 0.026, P < 0.05). In addition, the median OS after second resection in the IBEB group was also significantly longer than in the control group (11.0 vs. 8.0 months; log rank χ2 = 4.23, P = 0.04, P < 0.05). Conclusion: These hypothesis-generating results from a small cohort of subjects suggest putative clinical benefit in OS and LPFS associated with maximal safe re-resection of recurrent GBM with IBEB versus re-resection and standard adjuvant therapy, a hypothesis that deserves further testing in an appropriately powered clinical trial.This publication has 47 references indexed in Scilit:
- NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modalityEuropean Journal of Cancer, 2012
- Reirradiation of Large-Volume Recurrent Glioma With Pulsed Reduced-Dose-Rate RadiotherapyInternational Journal of Radiation Oncology*Biology*Physics, 2011
- Hypofractionated Stereotactic Radiation Therapy: An Effective Therapy for Recurrent High-Grade GliomasJournal of Clinical Oncology, 2010
- Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial GlioblastomaJournal of Clinical Oncology, 2010
- Bevacizumab Alone and in Combination With Irinotecan in Recurrent GlioblastomaJournal of Clinical Oncology, 2009
- Safety and Efficacy of Bevacizumab With Hypofractionated Stereotactic Irradiation for Recurrent Malignant GliomasInternational Journal of Radiation Oncology*Biology*Physics, 2009
- Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent GlioblastomaJournal of Clinical Oncology, 2009
- GliaSite Brachytherapy for Treatment of Recurrent Malignant Gliomas: A Retrospective Multi-institutional AnalysisNeurosurgery, 2006
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaThe New England Journal of Medicine, 2005
- Debulking or biopsy of malignant glioma in elderly people – a randomised studyActa Neurochirurgica, 2003